Estrella Immunopharma, INC

Estrella Immunopharma, Inc. announced the results of its Combined 2025/2026 Annual Meeting of Stockholders, where the appointment of Macias Gini & OConnell LLP as its independent registered public accounting firm was ratified.

Estrella Immunopharma, Inc. received a Nasdaq notice for failing to hold its annual shareholder meeting, but plans to submit a compliance plan and convene a meeting by April 2026.

Estrella Immunopharma completed an $8.0 million registered direct offering and concurrent private placement to fund general corporate purposes and working capital.

Estrella Immunopharma's EB103 CD19 CAR-T therapy has advanced to Phase II of its STARLIGHT-1 trial following positive safety and efficacy data, including a 100% complete response rate in the high-dose Phase I cohort.

Estrella Immunopharma announced the successful completion of the second dose cohort in its STARLIGHT-1 Phase I/II clinical trial of EB103, reporting a 100% complete response rate.

Estrella Immunopharma, Inc. announced it has regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements.

Estrella Immunopharma, a clinical-stage biopharmaceutical company, reported increased net losses and expenses for Q3 2025, while advancing its STARLIGHT-1 clinical trial and addressing internal control weaknesses.

Estrella Immunopharma reported increased net losses and a growing accumulated deficit, receiving two Nasdaq non-compliance notices for minimum bid price and market value of listed securities.

Estrella Immunopharma's Q1 2025 results show a net loss of $2.1 million, driven by increased research and development expenses related to its T-cell therapy programs.

Estrella Immunopharma's Q1 2025 report reveals a net loss of $3.4 million, driven by increased research and development expenses, as the company continues to advance its T-cell therapy programs.

Estrella Immunopharma reported a net loss of $0.5 million for the first quarter of 2024, while advancing preparations for its Starlight-1 clinical trial.

Estrella Immunopharma reports its financial results for the quarter ended December 31, 2023, following its business combination and detailing its ongoing development of T-cell therapies.

Estrella Immunopharma, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.

Estrella Immunopharma details its financial performance for the six-month transition period ending December 31, 2024, highlighting ongoing clinical trials and strategic collaborations.

Estrella Immunopharma has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.

Estrella Immunopharma's 10-K filing outlines its capital structure, stock details, and regulatory environment, including its T-cell therapy development and strategic collaborations.

Estrella Immunopharma's Chief Financial Officer Jiandong Xu acquired 2,100 shares of common stock through multiple open market purchases.

Estrella Immunopharma's CEO, Cheng Liu, received incentive and nonstatutory share options totaling 1,000,000 shares on October 30, 2024.

Estrella Immunopharma's CFO, Jiandong Xu, received incentive and nonstatutory share options totaling 1,000,000 shares on October 30 and 31, 2024, respectively, with vesting schedules.

Estrella Immunopharma schedules its combined 2025/2026 annual meeting of stockholders for June 29, 2026, to ratify the appointment of its independent auditor.

Estrella Immunopharma, Inc. filed an Amendment No. 2 to its S-1 Registration Statement, primarily updating exhibits, with its auditor noting a going concern issue.

Estrella Immunopharma, a clinical-stage biopharmaceutical company, filed an S-1/A to register shares for resale, highlighting ongoing clinical trial progress for EB103 and recent capital raises amidst significant operating losses and going concern doubts.

Estrella Immunopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 2,541,206 shares of common stock by selling stockholders, while reporting continued operating losses and a going concern doubt.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Estrella Immunopharma, Inc.'s common stock as of March 31, 2026.